◆ NeutralSPRY

ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

GlobeNewswire Inc.·
ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

A securities class action lawsuit has been filed against ARS Pharmaceuticals (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about a July 1, 2026 coverage start date, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

Read Full Article at GlobeNewswire Inc.
← Back to Financial Intelligence